等待開盤
0.000
NaN.00%
New data from BioCryst Pharmaceuticals highlights that ORLADEYO significantly reduces hereditary angioedema (HAE) attacks across all age groups, with sustained safety and improved quality of life for patients. Studies show a substantial decrease in attack frequency and severity, alongside minimal adverse effects, further validating ORLADEYO as a long-term prophylactic treatment option.
2025-06-16 11:00